The Association Between Extra-Cutaneous Manifestations and Family History Among Patients with Neurofibromatosis in Misurata: A Case-Control Study
Keywords:
Neurofibromatosis, genetic disorder, Libyan patients, case-control studyAbstract
Neurofibromatosis refers to a group of complex, rare genetic disorders marked by a wide range of clinical findings but mainly involving the skin and central nervous system. This study was conducted to study the relationship between extracutaneous manifestations of neurofibromatosis and positive family history among Libyan patients. A retrospective single-center case-control study on patients diagnosed with neurofibromatosis registered in the dermatology department at Misrata Medical Center. Ethical approval was obtained. Data were collected from patients' files into an Excel sheet; thereafter, analyzed using SPSS software. 28 patients were included, with a mean age of 19.2 years and a standard deviation of 14.36. The female-to-male ratio was 2:1. The most common skin manifestation was hyperpigmented patches; 85% of patients (n=24) developed extracutaneous manifestations involving the eyes, oral cavity, nails, heart, and musculoskeletal system. Among these, 14 patients had a positive family history of neurofibromatosis. The odds ratio is 2.6667, and the P-value is 0.2721. Patients with a positive family history of neurofibromatosis were more likely to exhibit extracutaneous manifestations compared to those without a familial history. Although the odds ratio was high, statistical analysis did not show a very strong association. Further studies with a bigger sample size are required.
References
1) Evans, D.G.; Howard, E.; Giblin, C.; Clancy, T.; Spencer, H.; Huson, S.M.; Lallo, F. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am. J. Med. Genet. A 2010, 152A, 327.
2) Kallionpää, R.A.; Uusitalo, E.; Leppävirta, J.; Pöyhönen, M.; Peltonen, S.; Peltonen, J. Prevalence of neurofibromatosis type 1 in the Finnish population. Genet. Med. 2018, 20, 1082.
3) Ruggieri, M.; Huson, S.M. The clinical and diagnostic implications of mosaicism in the neurofibromatoses. Neurology 2001, 56, 1433.
4) Legius, E.; Messiaen, L.; Wolkenstein, P.; Pancza, P.; Avery, R.A.; Berman, Y.; Blakeley, J.; Babovic-Vuksanovic, D.; Cunha, K.S.; Ferner, R.; et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation. Genet. Med. 2021, 19.
5) Stephens, K.; Kayes, L.; Riccardi, V.M.; Rising, M.; Sybert, V.P.; Pagon, R.A. Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum. Genet. 1992, 88, 279.
6) Evans, D.G.; Hartley, C.L.; Smith, P.T.; King, A.T.; Bowers, N.L.; Tobi, S.; Wallace, A.J.; Perry, M.; Anup, R.; Lloyd, S.K.W.; et al. Incidence of mosaicism in 1055 de novo NF2 cases: Much higher than previous estimates with high utility of next-generation sequencing. Genet. Med. 2020, 22, 53
7) Evans, D.G.; Ramsden, R.T.; Shenton, A.; Gokhale, C.; Bowers, N.L.; Huson, S.M.; Pichert, G.; Wallace, A. Mosaicism in neurofibromatosis type 2: An update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J. Med. Genet. 2007, 44, 424.
8) Rasmussen, S.A.; Yang, Q.; Friedman, J.M. Mortality in neurofibromatosis 1: An analysis using U.S. death certificates. Am. J. Hum. Genet. 2001, 68, 1110–1118.
9) Godel, T.; Bäumer, P.; Farschtschi, S.; Gugel, I.; Kronlage, M.; Hofstadler, B.; Heiland, S.; Gelderblom, M.; Bendszus, M.; Mautner, V.F. Peripheral nervous system alterations in infant and adult neurofibromatosis type 2. Neurology 2019, 93, e590.
10) Picry, A.; Bonne, N.X.; Ding, J.; Aboukais, R.; Lejeune, J.P.; Baroncini, M.; Dubrulle, F.; Vincent, C. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: A volumetric consideration. Laryngoscope 2016, 126, 2358–2362.
